PTH and postmenopausal osteoporosis: Although the current postmenopausal osteoporosis treatments, including antiresorptive agents like bisphosphonates and selective estrogen receptor modulators (SERMs), and anabolic agents, such as parathyroid hormone (PTH) and teriparatide, provide mechanisms to control bone loss and stimulate bone formation, they exhibit limitations.